HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Kezar Life Sciences (NASDAQ:KZR) and maintained a $20 price target.
May 10, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kezar Life Sciences receives a reiterated Buy rating and a maintained $20 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could positively impact Kezar Life Sciences' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100